Trial Profile
Clinical trial to evaluate efficacy and safety of cyclophosphamide, bortezomib and dexamethasone (CBD) induction and autologous stem cell transplantation for patients for newly diagnosed multiple myeloma (NBMT-ASCT1201)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Mar 2022
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Lenalidomide (Primary) ; Autologous stem cell therapy; Cyclophosphamide; Dexamethasone; Dexamethasone; Granulocyte colony-stimulating factors; Melphalan
- Indications Multiple myeloma
- Focus Therapeutic Use
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association
- 23 Dec 2018 Status changed from active, no longer recruiting to completed.
- 08 Dec 2015 Status changed from recruiting to active, no longer recruiting as reported by University Hospital medical Information Network - Japan.